BCG制剂降低原发性肾病综合征医院感染率的临床研究

The clinical research on using BCG-PSN to reduce the nosocomial infection rate of PNS patients

目的 :观察卡介苗 (BCG)制剂卡介菌多糖核酸 (BCG -PSN)在治疗原发性肾病综合征 (PNS)时的医院感染率降低情况。方法 :对 96例PNS住院患者采用随机对照方法观察比较BCG -PSN治疗组和对照组的医院感染率及尿蛋白量下降程度的变化情况。结果 :BCG -PSN治疗组的医院感染率为 8 5 %,对照组为 2 6 5 %,两组间比较在统计学上有显著性差异。而尿蛋白量在BCG短疗程治疗中下降程度无差异。结论 :BCG -PSN可明显降低PNS的医院感染率。

Objective:To observe the nosocomial infection rate and the decrease of albuminuria during the process of treatment with Polysaccharide nucleic fraction of Bacillus Calmette Guerin(BCG-PSN) of the primary nephrotic syndrome (PNS) patients. Methods: The nosocomial infection rate and the decrease of albuminuria were observed in 96 PNS inpatients who were allocated randomly into the BCG-PSN study group and the contrlo group.Results: The nosocomial infection rate of BCG-PSN study group was 8.5%,and the rate of control group was 26.5%.There was obvious difference in the nosocomial infection rate between BCG-PSN study group and the control group.There was no difference in the decrease of albuminuria between the two groups.Conclusion: BCG-PSN can obviously reduce the nosocomial infection rate of PNS patients.